ZHAOKE OPHTH (6622) expects three products to be approved successively this year
I'm LongbridgeAI, I can summarize articles.
ZHAOKE OPHTH Chairman Li Xiaoyi expects that in the second half of this year, multiple products will be approved one after another, including atropine sulfate eye drops for controlling myopia in adolescents, cyclosporine eye gel for treating dry eye syndrome, and bevacizumab intravitreal injection. In addition, the group plans to expand its international network to Latin America or South America
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tasty Money The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments